ResultsIQ

ResultsIQ › Latest results › GPT Healthcare Limited

GPT Healthcare Limited Q2 FY27 earnings call summary

NSE: GPTHEALTH · BSE: 544131

Earnings call of 6 Nov 2026, summarised by AI from the filing.

Management reiterated 15% to 16% revenue growth over last year for FY27.

Key takeaways

  1. FY27 guidance Management reiterated 15% to 16% revenue growth over last year for FY27.
  2. Raipur delay Raipur monthly breakeven pushed to Q1 FY28 from earlier Q3 FY27 guidance after clinical talent attrition.
  3. Volume driver Almost 11% rise in inpatient volumes lifted throughput and occupancy across the network.
  4. Competition risk Artemis's entry into Raipur caused clinical attrition and lower productivity, delaying breakeven.

Original filing on BSE

GPT Healthcare Limited Q2 FY27 results

As filed: Revenue ₹136 cr (+14% year on year), EBITDA ₹26.9 cr (+17% year on year), PAT ₹15.4 cr (+40% year on year), EBITDA margin 19.8% (+50 bps).

The Q2 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q1 FY27: Revenue ₹126 cr (+18% year on year), EBITDA ₹24.2 cr (+42% year on year), PAT ₹12.7 cr (+59% year on year), EBITDA margin 19.2% (+326 bps). Score 85 of 100, Above trend. Revenue growth was above the company's own trend; EBITDA and profit growth were well above it. EBITDA margin rose 326 bps year on year. Profit fell 13% from last quarter. Share price after the results: −8.0% in 30 days (Nifty 500: −2.4%).
  • Q4 FY26: Revenue ₹126 cr (+25% year on year), EBITDA ₹23.4 cr (+17% year on year), PAT ₹14.6 cr (+12% year on year), EBITDA margin 18.5% (−132 bps). Score 82 of 100, Above trend. Revenue and EBITDA growth were well above the company's own trend; profit growth was above it. EBITDA margin fell 132 bps year on year. Tax rate 8%. Share price after the results: +4.4% in 30 days (Nifty 500: +2.9%).
  • Q3 FY26: Revenue ₹120 cr (+18% year on year), EBITDA ₹20.7 cr (−6% year on year), PAT ₹9.4 cr (−22% year on year), EBITDA margin 17.2% (−433 bps). Score 47 of 100, In line with trend. Revenue growth was well above the company's own trend; EBITDA growth was below it; profit growth was well below it. EBITDA margin fell 433 bps year on year. Profit fell 15% from last quarter. Share price after the results: −5.7% in 30 days (Nifty 500: −1.9%).
  • Q2 FY26: Revenue ₹119 cr (+12% year on year), EBITDA ₹23.0 cr (−4% year on year), PAT ₹11.0 cr (−27% year on year), EBITDA margin 19.3% (−331 bps). Score 30 of 100, Below trend. EBITDA margin fell 331 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −5.4% in 30 days (Nifty 500: 0.0%).
  • Q1 FY26: Revenue ₹107 cr (+9% year on year), EBITDA ₹17.0 cr (−11% year on year), PAT ₹8.0 cr (−20% year on year), EBITDA margin 15.9% (−350 bps). Score 27 of 100, Below trend. EBITDA margin fell 350 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 38% from last quarter. Share price after the results: −13.8% in 30 days (Nifty 500: +0.7%).
  • Q4 FY25: Revenue ₹101 cr (+2% year on year), EBITDA ₹20.0 cr (−13% year on year), PAT ₹13.0 cr (0% year on year), EBITDA margin 19.8% (−343 bps). Score 24 of 100, Below trend. EBITDA margin fell 343 bps year on year. Not enough history for a trend yet: scored on growth alone. Share price after the results: −7.6% in 28 days (Nifty 500: +1.1%).
  • Q3 FY25: Revenue ₹102 cr (+5% year on year), EBITDA ₹22.0 cr (0% year on year), PAT ₹12.0 cr (+9% year on year), EBITDA margin 21.6% (−111 bps). Score 36 of 100, Below trend. EBITDA margin fell 111 bps year on year. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

GPT Healthcare Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.